Unneeded, unscientific restrictions around access to abortion medication remain in place, perpetuating a two decade-long intrusion of politics where it does not belong. The incoming Biden-Harris Administration now has an opportunity to fix that.
The biotech industry should worry about politics being put ahead of public health — similar restrictions could be imposed on any technology or individual medicine that is feared because of its innovation, or because it is unpopular with a small, albeit vocal, group.